The concentrated selling by OrbiMed (a sophisticated healthcare investor) and a director at an average price of ~$45.50 suggests insiders are monetizing near current levels. Monitor for any upcoming clinical data readouts, regulatory updates, or secondary offerings that could explain the urgency. The absence of any insider buying alongside this selling is a bearish signal.
SION drugs
SION drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $43.31entry
- T+1 · 6mo ago +2.12%α +1.29% · $44.23
- T+5 · 6mo ago −0.44%α −1.94% · $43.12
- T+20 · 6mo ago −15.26%α −18.40% · $36.70
- T+60 · 4mo ago +13.74%α +9.91% · $49.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Sionna directors (OrbiMed Advisors and Peter Thompson) sold a combined $26.7M of stock over three days, representing ~1.3% of market cap. This is a material, concentrated sell-off by the company's largest institutional holder and a board member, occurring without any disclosed positive catalyst.
Key Financial Metrics
Key Facts
- Two directors sold a total of 586,904 shares for $26.7M over May 7-11, 2026.
- Total sales represent ~1.3% of SION's $2.0B market cap, exceeding the 0.5% materiality threshold.
- OrbiMed Advisors, a major institutional holder with board representation, sold 292,952 shares for $13.4M.
- Director Peter Thompson sold 292,952 shares for $13.4M in identical transactions.
- No insider purchases were reported in the cluster; the net direction is entirely selling.
- The cluster follows $31.7M in insider sales over the prior 30 days, accelerating the sell-off pattern.
Financial Impact
Total insider sales of $26.7M, representing 1.3% of SION's $2.0B market cap.
Risk Factors
- Insiders may be selling ahead of negative clinical trial results or regulatory setbacks.
- Continued insider selling could pressure the stock and signal lack of confidence in near-term catalysts.
- OrbiMed's large sell-down may indicate a strategic reduction in its position, potentially leading to further overhang.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SION-1778541268760 |
Track record
22 reports on SION
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers